eBay Inc vs Novo Nordisk A/S — how do they compare? eBay Inc trades at $111.88 (market cap $49.83B), while Novo Nordisk A/S trades at $38.62 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 3.3× eBay Inc's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold eBay Inc for 134 Days and Novo Nordisk A/S for 116 Days on average.
| EBAY | NVO | |
|---|---|---|
Market Cap | $49.83B | $165.31B |
Volume | 2,986,953 | 11,432,838 |
Sector | Consumer Cyclical | Health |
52-Week High | $118.96 | $63.98 |
52-Week Low | $79.41 | $35.29 |
Typical Hold Time | 134 Days | 116 Days |
Enterprise Value | $53.65B | $179.56B |
Dividend Yield | 1.11% | 4.71% |
Signals from Pluang's Aura AI — not financial advice
EBAY trades at $112.19, up 4.27% today, showing strong momentum with consistent earnings beats in recent quarters. The stock maintains bullish technical signals with moving averages supporting upward trends, while fundamentals reveal robust profitability with 72.05% gross margins and 18.57% net income margins. Recent corporate developments include a $0.31 dividend declaration and strategic focus on collectibles and live commerce growth initiatives.
EBAY presents a favorable risk-reward profile with analyst consensus target of $117.68 offering 4.9% upside potential. The company's strong cash flow generation and debt reduction strategy provide financial stability, though competitive pressures from Amazon's multi-platform tools and slowing advertising growth present headwinds. Institutional sentiment remains positive with 49% buy ratings.
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
eBay Inc. is a global commerce company. The Company's platforms are designed to enable sellers worldwide to organize and offer their inventory for sale and buyers to find and buy it. eBay's items can be new or used, plain or luxurious, commonplace or rare, trendy or one-of-a-kind.
Read more on EBAY →With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →